


Supplementary Figure 6



**Supplementary Figure 6: VDZ binding to T<sub>Reg</sub> and T<sub>Eff</sub> cells *in vitro* and *in vivo***

**(A)** Representative gating strategy. T<sub>Eff</sub> cells were characterised as CD4<sup>+</sup>CD127<sup>+</sup>CD25<sup>-</sup> cells, T<sub>Reg</sub> cells as CD4<sup>+</sup>CD127<sup>-</sup>CD25<sup>+</sup>Foxp3<sup>+</sup> cells. The expression of  $\alpha 4\beta 7$  integrin was determined prior to further analysis for free vedolizumab binding sites.

**(B)** Representative flow cytometry of T<sub>Reg</sub> and T<sub>Eff</sub> cells without fluorescently labelled vedolizumab as gating control for detection of free VDZ binding sites.

**(C)** Representative flow cytometry of T<sub>Reg</sub> and T<sub>Eff</sub> cells with free VDZ binding sites from a patient treated with vedolizumab. Stainings from week 2 and week 6 with respective VDZ trough levels indicated.